Chronic lymphocytic leukemia B-cell-derived TNFα impairs bone marrow myelopoiesis.
Immunology
Molecular Biology
Stem Cells Research
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
22 Jan 2021
22 Jan 2021
Historique:
received:
22
07
2020
revised:
15
11
2020
accepted:
22
12
2020
entrez:
18
1
2021
pubmed:
19
1
2021
medline:
19
1
2021
Statut:
epublish
Résumé
TNFα is implicated in chronic lymphocytic leukemia (CLL) immunosuppression and disease progression. TNFα is constitutively produced by CLL B cells and is a negative regulator of bone marrow (BM) myelopoiesis. Here, we show that co-culture of CLL B cells with purified normal human hematopoietic stem and progenitor cells (HSPCs) directly altered protein levels of the myeloid and erythroid cell fate determinants PU.1 and GATA-2 at the single-cell level within transitional HSPC subsets, mimicking
Identifiants
pubmed: 33458625
doi: 10.1016/j.isci.2020.101994
pii: S2589-0042(20)31191-3
pmc: PMC7797930
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101994Subventions
Organisme : NIAID NIH HHS
ID : T32 AI007425
Pays : United States
Informations de copyright
© 2020 The Author(s).
Déclaration de conflit d'intérêts
Research funding to S.A.P. has been provided from 10.13039/100014491Pharmacyclics, 10.13039/501100013650MorphoSys, Janssen, 10.13039/100004325AstraZeneca, 10.13039/100013252TG Therapeutics, 10.13039/100006436Celgene, 10.13039/100006483AbbVie, and Ascentage Pharma for clinical studies in which S.A.P. is a principal investigator. S.A.P. also participated in Advisory Board meetings of Pharmacyclics, AstraZeneca, Genentech, Gilead, GlaxoSmithKline, Verastem Oncology, and AbbVie (he was not personally compensated for his participation). Research funding to N.E.K. has been provided from Acerta Pharma BV, 10.13039/100006436Celgene, 10.13039/100004328Genentech, 10.13039/100014491Pharmacyclics, and Tolero Pharmaceutical. N.E.K. also participates in the data safety monitoring committees of Agios Pharm, Astra Zeneca, Celgene, Cytomx Therapeutics, Genentech, Infinity Pharm, Morpho-Sys, and Pharmacyclics (he was not personally compensated for his participation). All other authors declare no competing interests.
Références
Blood. 2000 Dec 15;96(13):4118-23
pubmed: 11110682
Lancet. 1988 Apr 30;1(8592):969-71
pubmed: 2896830
Blood. 1989 Apr;73(5):1242-6
pubmed: 2539214
Leukemia. 2002 May;16(5):911-9
pubmed: 11986954
Clin J Oncol Nurs. 2000 Sep-Oct;4(5):233-4, 236
pubmed: 11111455
Sci Rep. 2018 Mar 21;8(1):4970
pubmed: 29563571
Blood. 2001 Jan 1;97(1):256-63
pubmed: 11133769
Leukemia. 2013 Jan;27(1):170-82
pubmed: 22713648
Clin Exp Immunol. 1991 Aug;85(2):302-6
pubmed: 1864011
Leuk Res. 2005 Jul;29(7):829-39
pubmed: 15927678
Crit Rev Oncol Hematol. 2012 Apr;82(1):1-17
pubmed: 21605981
J Immunol Methods. 2009 Aug 15;347(1-2):70-8
pubmed: 19567251
Stem Cells. 2007 Jul;25(7):1814-22
pubmed: 17464085
Leuk Res. 2008 Feb;32(2):225-33
pubmed: 17675228
J Immunol. 1986 Jun 15;136(12):4487-95
pubmed: 3086433
Cell Stem Cell. 2007 Oct 11;1(4):416-27
pubmed: 18371378
Leukemia. 2016 Jan;30(1):163-72
pubmed: 26139429
J Exp Med. 2011 Aug 1;208(8):1563-70
pubmed: 21768269
Stem Cells Dev. 2014 Dec 15;23(24):2972-82
pubmed: 25055118
Br J Haematol. 2008 May;141(5):615-21
pubmed: 18373706
Cell. 1995 Dec 1;83(5):793-802
pubmed: 8521496
Methods Mol Biol. 2013;946:241-56
pubmed: 23179836
J Exp Med. 1996 Jun 1;183(6):2551-8
pubmed: 8676076
Nat Rev Dis Primers. 2017 Feb 09;3:17008
pubmed: 28179635
Int J Hematol. 2014 Nov;100(5):417-24
pubmed: 24638828
Blood. 2009 Mar 26;113(13):3050-8
pubmed: 19074730
J Exp Med. 1994 Mar 1;179(3):999-1004
pubmed: 8113691
Biochem Pharmacol. 2011 Jul 15;82(2):156-66
pubmed: 21501595
Leukemia. 2010 Jul;24(7):1249-57
pubmed: 20520638
Eur J Haematol. 1998 Jul;61(1):14-20
pubmed: 9688287
Cell. 2011 Jan 21;144(2):296-309
pubmed: 21241896
Front Biosci (Schol Ed). 2012 Jan 01;4:61-73
pubmed: 22202043
Haematologica. 2018 Apr;103(4):688-697
pubmed: 29326123
Sci Transl Med. 2017 Dec 20;9(421):
pubmed: 29263228
Semin Hematol. 2017 Jan;54(1):39-42
pubmed: 28088986
Acta Haematol. 2009;121(4):187-95
pubmed: 19468203
Blood. 2019 Feb 21;133(8):816-819
pubmed: 30301719
Front Cell Dev Biol. 2018 Oct 30;6:143
pubmed: 30425986
Blood. 2000 Oct 15;96(8):2641-8
pubmed: 11023493
Leukemia. 2019 Mar;33(3):638-652
pubmed: 30291337
PLoS One. 2018 Jun 6;13(6):e0198347
pubmed: 29874279
Arch Med Res. 2009 Jul;40(5):357-63
pubmed: 19766898
Blood. 2015 Jul 30;126(5):573-81
pubmed: 26084672
Immunity. 2002 Nov;17(5):665-76
pubmed: 12433372
Ann Hematol. 1991 May;62(5):151-5
pubmed: 2049459
Haematologica. 2017 Sep;102(9):1469-1476
pubmed: 28775118
Blood. 2001 Sep 15;98(6):1782-91
pubmed: 11535512
Cell Stem Cell. 2012 Feb 3;10(2):120-36
pubmed: 22305562
Nucleic Acids Res. 2012 Jul;40(13):5819-31
pubmed: 22492510
Am J Hematol. 2011 Oct;86(10):835-40
pubmed: 21812019
Blood. 1993 Oct 15;82(8):2379-85
pubmed: 7691258
Stem Cell Investig. 2014 Jun 01;1:12
pubmed: 27358858
Leuk Res. 1991;15(2-3):111-20
pubmed: 2016903
Blood. 1990 Jul 15;76(2):393-400
pubmed: 2114936
Int J Oncol. 2009 Mar;34(3):853-60
pubmed: 19212691
Blood. 2002 Aug 15;100(4):1215-9
pubmed: 12149200
Signal Transduct Target Ther. 2017;2:
pubmed: 29158945
J Interferon Cytokine Res. 2000 May;20(5):507-10
pubmed: 10841079
J Clin Invest. 1990 Aug;86(2):538-41
pubmed: 2384599
Stem Cells. 2013 Jul;31(7):1237-44
pubmed: 23559316